Drugs / Lifei Qingchang Granules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07523165 | Apr 2026 → Mar 2028 expected | bronchiectasis | The First Affiliated Hospital of Guangzhou Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lifei Qingchang Granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07523165 ↗ |
| Known as | LFQC | “Lifei Qingchang Granules (LFQC) is a traditional Chinese medicine formula used to treat acute exacerbations and prevent recurrence of bronchiectasis.” PMID 41192693 ↗ Nov 2025 |
| Action | Inhibit | “LFQC alleviates airway inflammation in bronchiectasis by inhibiting NET formation through the NOX2-p47 phox/ROS pathway” PMID 41192693 ↗ Nov 2025 |
| Modality | Traditional medicine (herbal / TCM) | “Lifei Qingchang Granules (LFQC) is a traditional Chinese medicine formula used to treat acute exacerbations and prevent recurrence of bronchiectasis.” PMID 41192693 ↗ Nov 2025 |
| Route | Oral | “Administered orally” NCT07523165 ↗ |